PPP3R1 Promoter Polymorphism (Allelic Variation) Affects Tacrolimus Treatment Efficacy by Modulating E2F6 Binding...

Area of Science:

• Pharmacogenomics
• Immunology
• Molecular Biology

Background:

• Tacrolimus (TAC) is a vital immunosuppressant in transplantation, but its effectiveness varies significantly among individuals due to its narrow therapeutic index.
• Identifying genetic factors influencing TAC pharmacodynamics is crucial for optimizing patient outcomes.

Purpose of the Study:

• To investigate the regulatory role of a novel PPP3R1 promoter polymorphism, rs4519508 C > T, in the tacrolimus pharmacodynamic pathway.
• To explore the impact of this polymorphism on gene expression and immune response to TAC.

Main Methods:

• Dual-luciferase reporter assays and bioinformatic analysis to assess allelic variation effects.
• Electrophoretic mobility shift assays (EMSA) to validate transcription factor binding.
• Quantitative real-time PCR (qRT-PCR), ELISA, and Western blots to determine TAC's immunosuppressive effects.

Main Results:

• The rs4519508 C > T polymorphism significantly enhanced PPP3R1 promoter activity.
• EMSA confirmed that the transcription factor E2F6 binds to the wild-type rs4519508 C allele but binds weakly to the mutant T allele.
• Downregulation of E2F6 increased downstream immune cytokine levels inhibited by TAC, an effect dependent on the rs4519508 genotype.

Conclusions:

• E2F6 suppresses PPP3R1 expression; the rs4519508 C > T polymorphism impairs E2F6 binding, increasing PPP3R1 levels and attenuating TAC's inhibition of immune cytokines.
• The PPP3R1 rs4519508 C > T polymorphism is a potential pharmacodynamic biomarker for predicting individual tacrolimus response variability in transplant patients.